EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series

Rachel S Goodman iD, Seungyeon Jung, Jessica Quintos, Douglas B Johnson

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Rachel S Goodman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, SCRIPS Foundation/Burroughs Wellcome Fund. D.B.J..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of metastatic melanoma patients that fail multiple lines of systemic therapy remains a significant challenge. There is limited literature regarding combination of anti-PD-1 and temozolomide, or of other chemotherapy agents, in melanoma. Here, we present a series of 3 patients with metastatic melanoma and their responses to nivolumab and temozolomide combination therapy after progression on several local/regional therapies, combination immune checkpoint inhibitors, and/or targeted therapies. The novel combinatory strategy led to remarkable responses in all 3 patients shortly after initiating treatment with tumor remission and symptomatic improvement. The first patient has had ongoing response 15 months after initiating treatment, although he has since discontinued temozolomide due to intolerance. The remaining 2 patients show ongoing response after 4 months, with good tolerability. This case series suggests that nivolumab and temozolomide may be a promising option in the setting of advanced melanoma refractory to standard treatments, and warrants further investigation in larger series.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntineoplastic AgentsMaleHumansNivolumabTemozolomideSalvage TherapyAntineoplastic Combined Chemotherapy ProtocolsIpilimumab

Stichwörter der Autor:innen

chemotherapyimmunotherapymelanomametastatic melanomanivolumabsalvage therapytemozolomide

Substanzen

NivolumabTemozolomideAntineoplastic AgentsIpilimumab

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA.
  • Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.

ORCID-Profile: Rachel S Goodman

Förderung

  • NCI NIH HHS
  • SCRIPS Foundation/Burroughs Wellcome Fund. D.B.J.

Zitieren

APA

Goodman, R. S., Jung, S., Quintos, J., & Johnson, D. B. (2023). Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series. The Oncologist. https://doi.org/10.1093/oncolo/oyad184

Vancouver

Goodman RS, Jung S, Quintos J, Johnson DB. Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series. The Oncologist. 2023. doi:10.1093/oncolo/oyad184

BibTeX
@article{Goodman2023,
  author = {Goodman, Rachel S and Jung, Seungyeon and Quintos, Jessica and Johnson, Douglas B},
  title = {Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad184}
}
Kostenlos starten →